Gonococcal Vaccine Project
A vaccine to prevent gonorrhoea and combat spread of AMR targeting LMICs
GONOCCOCAL VACCINE PROJECT
Neisseria gonorrhoeae (gonococcus) causes 82.4 million cases of the sexually transmitted infection, gonorrhoea, annually with women in low- and middle-income countries (LMICs) disproportionately affected. Complications include pelvic inflammatory disease, ectopic pregnancy, infertility, and infant blindness. Rapid emergence of multi-drug resistant gonococci threatens to make these infections untreatable. The need for a gonococcal vaccine is pressing, but currently none is available.
NEW VACCINE RESEARCH AND PRODUCT DEVELOPMENT
We are using native outer membrane vesicle (nOMV) technology to develop a candidate vaccine against gonococcus, GonoVac. The vaccine is immunogenic and able to accelerate the clearance of gonococcus in a preclinical infection model. We are currently conducting bioprocess studies and analytical development leading to the production of Good Manufacturing Practice (GMP)-quality vaccine lots for testing in humans. In parallel, we are investigating clinical samples from patients with gonorrhoea to understand the mechanisms of immunological protection against gonorrhoea and correlates of projection.
Read more about the project funding here